About: Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators
Creator	Dai, Bingling Liu, Rui Ma, Yujiao Wang, Wenjie Zhan, Yingzhuan Zhang, Dongdong Zhang, Yanmin
Source	PMC
abstract	Highly effective and attenuated dose schedules are good regimens for drug research and development. Combination chemotherapy is a good strategy in cancer therapy. We evaluated the antitumour effects of dihydroberberine combined with sunitinib (DCS) on the human non‐small cell lung cancer cell lines (NSCLC), A549, NCI‐H460, and NCI‐H1299 in vitro and in vivo. DCS showed synergic effects on NCI‐H460 cell proliferation, colony formation and transplantable tumour growth, which suggested dihydroberberine increases the sensitivity of lung carcinoma to sunitinib. Further studies indicated that DCS down‐regulated phosphorylation of JNK, p38, and NF‐κB in NCI‐H460 cells and tumours and suppressed the IκB and COX‐2 expression. In addition, DCS reduced the secretion of the pro‐inflammatory cytokine, interleukin‐1 (IL‐1), in tumours. Inhibition of p38 activation by DCS was a likely contributing factor in IL‐1 and COX‐2 down‐regulation. Consistent with these results, a genomewide microarray analysis found that DCS induced the expression of cell cycle signal molecules that are known to be affected by JNK and p38. The change of cell cycle, in turn, led to down‐regulation of JNK and p38, and further reduced IL‐1 secretion. Collectively, these findings highlight potential molecular mechanisms of DCS chemotherapeutic activity and suggest that DCS is an efficacious strategy in NSCLC therapy.
has issue date	2017-04-26(xsd:dateTime)
bibo:doi	10.1111/jcmm.13178
bibo:pmid	28444871
has license	cc-by
sha1sum (hex)	63a0d9767212d4316c91660dc4eedc8cb3fe527f
schema:url	https://doi.org/10.1111/jcmm.13178
resource representing a document's title	Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators
has PubMed Central identifier	PMC5618684
has PubMed identifier	28444871
schema:publication	J Cell Mol Med
resource representing a document's body	covid:63a0d9767212d4316c91660dc4eedc8cb3fe527f#body_text
is schema:about of	named entity 'DCS' named entity 'p38' named entity 'good' named entity 'sunitinib' covid:arg/63a0d9767212d4316c91660dc4eedc8cb3fe527f named entity 'colony' named entity 'antitumour' named entity 'JNK' named entity 'down-regulation' named entity 'turn' named entity 'efficacious' named entity 'cells' named entity 'The change' named entity 'Combination' named entity 'DCS' named entity 'cell cycle' named entity 'down-regulated' named entity 'secretion' named entity 'DCS' named entity 'NCI-H460' named entity 'chemotherapeutic' named entity 'p38' named entity 'down-regulation' named entity 'phosphorylation' named entity 'COX-2' named entity 'NCI-H460' named entity 'down-regulation' named entity 'microarray analysis' named entity 'pro-inflammatory cytokine' named entity 'NCI-H460' named entity 'tumour' named entity 'expression' named entity 'anti-NF' named entity 'inflammation' named entity 'multiple genes' named entity 'regulating the expression' named entity 'transmit signals' named entity 'NCI-H460' named entity 'growth factor' named entity 'Shanghai' named entity 'Becton Dickinson' named entity 'polyvinylidene fluoride' named entity 'thrice' named entity 'NCI-H460' named entity 'mice' named entity 'nuclear translocation' named entity 'catalyses' named entity 'inflammatory cells' named entity 'protein' named entity 'p110a' named entity 'staining' named entity 'synergistic' named entity 'Western blotting' named entity 'cell proliferation' named entity 'NCI-H460' named entity 'mitotic cell cycle' named entity 'MAPKs' named entity 'tumour' named entity 'GAPDH' named entity 'H1299' named entity 'NCI-H460' named entity 'China' named entity 'phosphorylation' named entity 'down-regulating' named entity 'NCI-H460' named entity 'VEGFR' named entity 'NCI-H460' named entity 'SCID' named entity 'protein expression' named entity 'inflammation' named entity 'Flow cytometry' named entity 'NCI-H460' named entity '5.1' named entity 'cancer cell lines' named entity 'phosphatase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software